Thrombosis is the most important underlying mechanism of coronary artery disease and embolic stroke. Hence, antithrombotic therapy is widely used in these scenarios. However, not all patients achieve the same degree of benefit from antithrombotic agents, and a considerable number of treated patients will continue to experience a new thrombotic event. Such lack of clinical benefit may be related to a wide variability of responses to antithrombotic treatment among individuals (i.e., interindividual heterogeneity). Several factors have been identified in this interindividual heterogeneity in response to antithrombotic treatment. Pharmacogenetics has emerged as a field that identifies specific gene variants able to explain the variability in patient response to a given drug. Polymorphisms affecting the disposition, metabolism, transporters, or targets of a drug all can be implicated in the modification of an individuals antithrombotic drug response and therefore the safety and efficacy of the aforementioned drug. The present paper reviews the modulating role of different polymorphisms on individuals responses to antithrombotic drugs commonly used in clinical practice. © 2009 American College of Cardiology Foundation.

Pharmacogenetics in Cardiovascular Antithrombotic Therapy

Capranzano, Piera
Writing – Review & Editing
;
2009-01-01

Abstract

Thrombosis is the most important underlying mechanism of coronary artery disease and embolic stroke. Hence, antithrombotic therapy is widely used in these scenarios. However, not all patients achieve the same degree of benefit from antithrombotic agents, and a considerable number of treated patients will continue to experience a new thrombotic event. Such lack of clinical benefit may be related to a wide variability of responses to antithrombotic treatment among individuals (i.e., interindividual heterogeneity). Several factors have been identified in this interindividual heterogeneity in response to antithrombotic treatment. Pharmacogenetics has emerged as a field that identifies specific gene variants able to explain the variability in patient response to a given drug. Polymorphisms affecting the disposition, metabolism, transporters, or targets of a drug all can be implicated in the modification of an individuals antithrombotic drug response and therefore the safety and efficacy of the aforementioned drug. The present paper reviews the modulating role of different polymorphisms on individuals responses to antithrombotic drugs commonly used in clinical practice. © 2009 American College of Cardiology Foundation.
2009
antithrombotic therapy; pharmacogenetics; polymorphism; Cardiovascular Diseases; Fibrinolytic Agents; Humans; Treatment Outcome; Pharmacogenetics; Cardiology and Cardiovascular Medicine
File in questo prodotto:
File Dimensione Formato  
Pharmacogenetics in Cardiovascular Antithrombotic Therapy.pdf

solo gestori archivio

Tipologia: Versione Editoriale (PDF)
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 603.42 kB
Formato Adobe PDF
603.42 kB Adobe PDF   Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11769/325274
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 91
  • ???jsp.display-item.citation.isi??? 80
social impact